MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation DSO Ratio 2011-2026 | AGTC
Annual DSO Ratio Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 0.114 | 3.17 | 1.61 | 7.35 | 137 | 157 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 157 | 0.114 | 51.1 |
Quarterly DSO Ratio Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.9 | 3.64 | 12.3 | 7.8 | 28.6 | 21.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.6 | 3.64 | 14.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
62.9 | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
70.9 | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Immutep Limited
IMMP
|
351 | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Concert Pharmaceuticals
CNCE
|
147 | - | - | $ 401 M | USA |
 |
Celsion Corporation
CLSN
|
15.6 | - | -6.63 % | $ 13.9 M | USA |